Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Markets and Markets to hold a virtual event » 09:46
06/25/20
06/25
09:46
06/25/20
09:46
ALLO

Allogene Therapeutics

$43.29 /

+ (+0.00%)

, CELG

Bought by BMY

$108.26 /

+ (+0.00%)

, MRK

Merck

$75.62 /

-0.22 (-0.29%)

, PFE

Pfizer

$32.09 /

-0.11 (-0.34%)

, QGEN

Qiagen

$43.07 /

+0.1 (+0.23%)

, REGN

Regeneron

$608.77 /

+3.675 (+0.61%)

, TAK

Takeda Pharmaceutical

$18.25 /

-0.08 (-0.44%)

Next-Gen 3rd Annual…

Next-Gen 3rd Annual Immuno-Oncology Virtual Congress will be held on June 25-26. Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

CELG Bought by BMY
$108.26 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

06/08/20 SunTrust
Allogene Therapeutics price target raised to $50 from $32 at SunTrust
06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
CELG Bought by BMY
$108.26 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
MRK Merck
$75.62 /

-0.22 (-0.29%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
PFE Pfizer
$32.09 /

-0.11 (-0.34%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
REGN Regeneron
$608.77 /

+3.675 (+0.61%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

CELG Bought by BMY
$108.26 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 05:55
06/24/20
06/24
05:55
06/24/20
05:55
A

Agilent

$89.36 /

+0.81 (+0.91%)

, ABBV

AbbVie

$97.28 /

+0.03 (+0.03%)

, ADPT

Adaptive Biotechnologies

$46.95 /

+1.04 (+2.27%)

, AZN

AstraZeneca

$54.24 /

+0.8 (+1.50%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$187.74 /

+4.42 (+2.41%)

, BMY

Bristol-Myers

$58.41 /

+0.85 (+1.48%)

, BNTX

BioNTech

$52.80 /

-4.64 (-8.08%)

, CRL

Charles River

$175.05 /

-0.12 (-0.07%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$83.33 /

+0.26 (+0.31%)

, GILD

Gilead

$75.01 /

-0.61 (-0.81%)

, PFE

Pfizer

$32.78 /

-0.33 (-1.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVCR

Novocure

$62.71 /

-0.31 (-0.49%)

, NTRA

Natera

$46.65 /

+0.36 (+0.78%)

, SNY

Sanofi

$52.49 /

-0.06 (-0.11%)

, RUBY

Rubius Therapeutics

$6.52 /

-0.02 (-0.31%)

, NEO

NeoGenomics

$29.05 /

+0.49 (+1.72%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$25.06 /

-0.75 (-2.91%)

, QGEN

Qiagen

$42.87 /

+0.31 (+0.73%)

, LLY

Eli Lilly

$159.35 /

-1.06 (-0.66%)

, PKI

PerkinElmer

$99.11 /

+1.08 (+1.10%)

, GSK

GlaxoSmithKline

$41.60 /

+0.37 (+0.90%)

, ILMN

Illumina

$367.22 /

+7.02 (+1.95%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

A Agilent
$89.36 /

+0.81 (+0.91%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

06/23/20
Fly Intel: Top five analyst upgrades
06/23/20 Atlantic Equities
AbbVie upgraded to Overweight from Neutral at Atlantic Equities
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/23/20 Berenberg
Bayer price target raised to EUR 86 from EUR 82 at Berenberg
06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$175.05 /

-0.12 (-0.07%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$83.33 /

+0.26 (+0.31%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$75.01 /

-0.61 (-0.81%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$32.78 /

-0.33 (-1.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$62.71 /

-0.31 (-0.49%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.65 /

+0.36 (+0.78%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
ILMN Illumina
$367.22 /

+7.02 (+1.95%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

Hot Stocks
Qiagen sees pre-tax capital gain of $120M on ArcherDX minority investment » 13:54
06/23/20
06/23
13:54
06/23/20
13:54
QGEN

Qiagen

$42.91 /

+0.35 (+0.82%)

, NVTA

Invitae

$29.73 /

+2.74 (+10.15%)

Qiagen (QGEN) announces…

Qiagen (QGEN) announces that according to the intended business combination between Invitae (NVTA) and ArcherDX, Qiagen could realize a significant pre-tax capital gain from its minority investment in ArcherDX. As of June 23, Qiagen held an equity stake on a fully diluted basis in ArcherDX of approximately 8%. The current book value of Qiagen's shareholding in ArcherDX is $20M. Under the terms of the combination agreement as disclosed publicly, Invitae will acquire ArcherDX for upfront consideration consisting of 30M shares of Invitae common stock and $325M in cash, plus up to an additional 27M shares of Invitae common stock payable in connection with the achievement of certain milestones. The consideration is subject to customary purchase-price adjustments. Based on the closing share price of Invitae on the New York Stock Exchange of $27.05 on June 22, and assuming a full payout of the contingent consideration and further preliminary information taken into account, Qiagen estimates that its pre-tax capital gain could be approximately $120M. Qiagen has held the investment in ArcherDX since 2015, when it acquired the enzymes solutions unit of Enzymatics, a U.S.-based supplier of enzymes used in next-generation sequencing and other genetic analysis technologies.

ShowHide Related Items >><<
QGEN Qiagen
$42.91 /

+0.35 (+0.82%)

NVTA Invitae
$29.73 /

+2.74 (+10.15%)

QGEN Qiagen
$42.91 /

+0.35 (+0.82%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
NVTA Invitae
$29.73 /

+2.74 (+10.15%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
05/06/20 SVB Leerink
Invitae price target raised to $25 from $20 at SVB Leerink
04/02/20 Oppenheimer
Invitae price target lowered to $25 from $32 at Oppenheimer
02/20/20 Cowen
Invitae price target raised to $30 from $20 at Cowen
QGEN Qiagen
$42.91 /

+0.35 (+0.82%)

NVTA Invitae
$29.73 /

+2.74 (+10.15%)

QGEN Qiagen
$42.91 /

+0.35 (+0.82%)

QGEN Qiagen
$42.91 /

+0.35 (+0.82%)

NVTA Invitae
$29.73 /

+2.74 (+10.15%)

QGEN Qiagen
$42.91 /

+0.35 (+0.82%)

NVTA Invitae
$29.73 /

+2.74 (+10.15%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
A

Agilent

$88.55 /

-0.27 (-0.30%)

, ABBV

AbbVie

$97.25 /

+0.53 (+0.55%)

, ADPT

Adaptive Biotechnologies

$45.91 /

+1.24 (+2.78%)

, AZN

AstraZeneca

$53.44 /

+0.39 (+0.74%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$183.32 /

+0.75 (+0.41%)

, BMY

Bristol-Myers

$57.56 /

+1.22 (+2.17%)

, BNTX

BioNTech

$57.44 /

+6.02 (+11.71%)

, CRL

Charles River

$175.17 /

-3.21 (-1.80%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$83.07 /

+4.14 (+5.25%)

, GILD

Gilead

$75.62 /

-1.61 (-2.08%)

, PFE

Pfizer

$33.11 /

-0.32 (-0.96%)

, NVS

Novartis

$90.58 /

-0.55 (-0.60%)

, NVCR

Novocure

$63.02 /

-0.33 (-0.52%)

, NTRA

Natera

$46.29 /

-0.16 (-0.34%)

, SNY

Sanofi

$52.55 /

+0.25 (+0.48%)

, RUBY

Rubius Therapeutics

$6.54 /

+0.07 (+1.08%)

, NEO

NeoGenomics

$28.56 /

+0.17 (+0.60%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$25.81 /

-0.23 (-0.88%)

, QGEN

Qiagen

$42.56 /

-0.03 (-0.07%)

, LLY

Eli Lilly

$160.41 /

+0.51 (+0.32%)

, PKI

PerkinElmer

$98.03 /

-0.48 (-0.49%)

, GSK

GlaxoSmithKline

$41.23 /

+0.11 (+0.27%)

, ILMN

Illumina

$360.20 /

-10.23 (-2.76%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

NTRA Natera
$46.29 /

-0.16 (-0.34%)

NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$175.17 /

-3.21 (-1.80%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

A Agilent
$88.55 /

-0.27 (-0.30%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$175.17 /

-3.21 (-1.80%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$83.07 /

+4.14 (+5.25%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$75.62 /

-1.61 (-2.08%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$33.11 /

-0.32 (-0.96%)

06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
NVS Novartis
$90.58 /

-0.55 (-0.60%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$63.02 /

-0.33 (-0.52%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.29 /

-0.16 (-0.34%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
ILMN Illumina
$360.20 /

-10.23 (-2.76%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

NTRA Natera
$46.29 /

-0.16 (-0.34%)

NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

CRL Charles River
$175.17 /

-3.21 (-1.80%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 08:42
06/22/20
06/22
08:42
06/22/20
08:42
A

Agilent

$88.82 /

+0.6 (+0.68%)

, ABBV

AbbVie

$96.72 /

+0.45 (+0.47%)

, ADPT

Adaptive Biotechnologies

$44.67 /

+0.14 (+0.31%)

, AZN

AstraZeneca

$53.05 /

+0.39 (+0.74%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$182.57 /

+5.09 (+2.87%)

, BMY

Bristol-Myers

$56.34 /

+0.35 (+0.63%)

, BNTX

BioNTech

$51.42 /

+0.48 (+0.94%)

, CRL

Charles River

$178.38 /

-0.31 (-0.17%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$78.93 /

-0.62 (-0.78%)

, GILD

Gilead

$77.23 /

+3.18 (+4.29%)

, PFE

Pfizer

$33.43 /

+0.2 (+0.60%)

, NVS

Novartis

$91.13 /

+1.47 (+1.64%)

, NVCR

Novocure

$63.35 /

+0.83 (+1.33%)

, NTRA

Natera

$46.45 /

+0.43 (+0.93%)

, SNY

Sanofi

$52.30 /

+0.84 (+1.63%)

, RUBY

Rubius Therapeutics

$6.47 /

+0.09 (+1.41%)

, NEO

NeoGenomics

$28.39 /

+0.145 (+0.51%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$26.04 /

-1.46 (-5.31%)

, QGEN

Qiagen

$42.59 /

+0.17 (+0.40%)

, LLY

Eli Lilly

$159.90 /

-1.14 (-0.71%)

, PKI

PerkinElmer

$98.51 /

+0.565 (+0.58%)

, GSK

GlaxoSmithKline

$41.12 /

+0.18 (+0.44%)

, ILMN

Illumina

$370.43 /

+8.18 (+2.26%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

NTRA Natera
$46.45 /

+0.43 (+0.93%)

NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$178.38 /

-0.31 (-0.17%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

A Agilent
$88.82 /

+0.6 (+0.68%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$178.38 /

-0.31 (-0.17%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$78.93 /

-0.62 (-0.78%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$77.23 /

+3.18 (+4.29%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$33.43 /

+0.2 (+0.60%)

06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
06/08/20 Piper Sandler
Opko Health, Pfizer data show IGF-1 normal at ENDO, says Piper Sandler
NVS Novartis
$91.13 /

+1.47 (+1.64%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$63.35 /

+0.83 (+1.33%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.45 /

+0.43 (+0.93%)

06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
05/07/20 JPMorgan
Natera upgraded to Overweight from Neutral at JPMorgan
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
ILMN Illumina
$370.43 /

+8.18 (+2.26%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

NTRA Natera
$46.45 /

+0.43 (+0.93%)

NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

CRL Charles River
$178.38 /

-0.31 (-0.17%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

Hot Stocks
T2 Biosystems appoints new board appointments including Qiagen CEO » 16:13
06/15/20
06/15
16:13
06/15/20
16:13
TTOO

T2 Biosystems

$1.63 /

-0.04 (-2.40%)

, QGEN

Qiagen

$43.33 /

+0.36 (+0.84%)

T2 Biosystems (TTOO) …

T2 Biosystems (TTOO) announced three new Board of Director appointments. The three new directors will add significant clinical and commercialization experience and expand board diversity, coupled with a strong understanding of the company's customer base. The new appointments include: Thierry Bernard, Chief Executive Officer, QIAGEN (QGEN); Dr. Ninfa Saunders, President and Chief Executive Officer, Navicent Health; and Robin Toft, Founder and Chief Executive Officer, Toft Group, a ZRG company. "We are thrilled to add to our Board three individuals whose commercial expertise and combined background in molecular diagnostics, clinical care, and life science leadership will bring invaluable perspective and insight to our business, helping us to achieve our goals of accelerating our sales, improving our operations, and advancing our pipeline," said John Sperzel, President and Chief Executive Officer, T2 Biosystems. "Our commitment to developing innovative technology that helps save lives and improve patient outcomes remains steadfast, and adding these three industry leaders will bolster our efforts to accomplish that in the coming months and years."

ShowHide Related Items >><<
TTOO T2 Biosystems
$1.63 /

-0.04 (-2.40%)

QGEN Qiagen
$43.33 /

+0.36 (+0.84%)

TTOO T2 Biosystems
$1.63 /

-0.04 (-2.40%)

02/06/20 JonesTrading
T2 Biosystems upgraded to Buy from Hold at JonesTrading
01/23/20 Alliance Global Partners
T2 Biosystems upgraded to Buy from Neutral at Alliance Global Partners
11/26/19 Janney Montgomery Scott
T2 Biosystems downgraded to Neutral at Janney Montgomery Scott
11/26/19 Janney Montgomery Scott
T2 Biosystems downgraded to Neutral from Buy at Janney Montgomery Scott
QGEN Qiagen
$43.33 /

+0.36 (+0.84%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
TTOO T2 Biosystems
$1.63 /

-0.04 (-2.40%)

QGEN Qiagen
$43.33 /

+0.36 (+0.84%)

QGEN Qiagen
$43.33 /

+0.36 (+0.84%)

TTOO T2 Biosystems
$1.63 /

-0.04 (-2.40%)

QGEN Qiagen
$43.33 /

+0.36 (+0.84%)

QGEN Qiagen
$43.33 /

+0.36 (+0.84%)

Hot Stocks
Qiagen believes Thermo Fisher offer is 'full, fair, attractive' » 14:32
06/12/20
06/12
14:32
06/12/20
14:32
QGEN

Qiagen

$42.53 /

-0.56 (-1.30%)

, TMO

Thermo Fisher

$333.70 /

-2.11 (-0.63%)

Qiagen (QGEN) continues…

Qiagen (QGEN) continues to believe Thermo Fisher's (TMO) offer is "full, fair, attractive," a spokesman for Qiagen told Bloomberg in a phone interview. The comment comes after Glass Lewis's recommendation that Qiagen shareholders vote against the "Top Up" proposal under the Thermo Fisher deal.

ShowHide Related Items >><<
TMO Thermo Fisher
$333.70 /

-2.11 (-0.63%)

QGEN Qiagen
$42.53 /

-0.56 (-1.30%)

QGEN Qiagen
$42.53 /

-0.56 (-1.30%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
TMO Thermo Fisher
$333.70 /

-2.11 (-0.63%)

04/23/20 SVB Leerink
Thermo Fisher price target raised to $365 from $330 at SVB Leerink
04/23/20 Needham
Thermo Fisher price target raised to $383 from $341 at Needham
04/21/20 Wells Fargo
Danaher price target raised to $170 from $155 at Wells Fargo
03/30/20 Wells Fargo
Thermo Fisher price target lowered to $300 from $345 at Wells Fargo
TMO Thermo Fisher
$333.70 /

-2.11 (-0.63%)

QGEN Qiagen
$42.53 /

-0.56 (-1.30%)

TMO Thermo Fisher
$333.70 /

-2.11 (-0.63%)

QGEN Qiagen
$42.53 /

-0.56 (-1.30%)

TMO Thermo Fisher
$333.70 /

-2.11 (-0.63%)

QGEN Qiagen
$42.53 /

-0.56 (-1.30%)

TMO Thermo Fisher
$333.70 /

-2.11 (-0.63%)

QGEN Qiagen
$42.53 /

-0.56 (-1.30%)

Over a month ago
Hot Stocks
Qiagen launches novel solutions in oncology » 16:13
05/28/20
05/28
16:13
05/28/20
16:13
QGEN

Qiagen

$43.46 /

+0.41 (+0.95%)

Qiagen announced the…

Qiagen announced the launch of novel solutions enabling faster, better analysis of genomic variations in cancer - accelerating multiple applications of Precision Medicine. Qiagen is showcasing its broad portfolio of Sample to Insight solutions for cancer in connection with the 2020 American Society of Clinical Oncology Annual Meeting, being held virtually from May 29-31. "While we serve the world's needs for testing tools in the COVID-19 pandemic, QIAGEN also continues to deliver cutting-edge molecular solutions for cancer research and improving patient outcomes. We are fully engaged with customers in oncology, making the most of digital technologies and virtual settings such as the 2020 ASCO Annual Meeting," said Thierry Bernard, Chief Executive Officer at Qiagen. "Our new QCI Interpret One clinical decision support software solutions, QIAseq Pan-cancer Multimodal and QIAseq Targeted Methyl panels provide oncology researchers with valuable tools and additions for variant interpretation, liquid biopsy applications as well as comprehensive genomic profiling (CGP) and biomarker discovery. They create true Sample to Insight solutions for a variety of oncology research applications."

ShowHide Related Items >><<
QGEN Qiagen
$43.46 /

+0.41 (+0.95%)

QGEN Qiagen
$43.46 /

+0.41 (+0.95%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
QGEN Qiagen
$43.46 /

+0.41 (+0.95%)

QGEN Qiagen
$43.46 /

+0.41 (+0.95%)

QGEN Qiagen
$43.46 /

+0.41 (+0.95%)

QGEN Qiagen
$43.46 /

+0.41 (+0.95%)

Hot Stocks
Thermo Fisher publishes offer document for voluntary tender offer for Qiagen » 05:44
05/18/20
05/18
05:44
05/18/20
05:44
TMO

Thermo Fisher

$343.03 /

+6.54 (+1.94%)

, QGEN

Qiagen

$42.08 /

-0.24 (-0.57%)

Thermo Fisher Scientific…

Thermo Fisher Scientific (TMO) published the offer document for its voluntary tender offer for all of the ordinary shares of QIAGEN N.V. (QGEN) at an offer price of EUR 39 per share in cash, following approval of the publication by the German Federal Financial Supervisory Authority. The period for acceptance of the Tender Offer commenced on May 18, and is scheduled to end at midnight Frankfurt am Main Local Time or 6:00 PM New York Local Time on July 27. The Tender Offer is subject to certain customary closing conditions, including, among others, the receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at QIAGEN's general meeting of shareholders, and a minimum acceptance threshold of at least 75% of QIAGEN's issued and outstanding ordinary share capital as of the end of the acceptance period. The conditions to the Tender Offer are set forth in their entirety in section 12 of the Offer Document. The QIAGEN Managing Board and Supervisory Board have unanimously recommended that QIAGEN shareholders accept the Tender Offer by tendering their shares and vote in favor of each of the transaction resolutions at the General Meeting. The transaction is expected to close in the first half of 2021 as previously announced.

ShowHide Related Items >><<
TMO Thermo Fisher
$343.03 /

+6.54 (+1.94%)

QGEN Qiagen
$42.08 /

-0.24 (-0.57%)

TMO Thermo Fisher
$343.03 /

+6.54 (+1.94%)

04/23/20 SVB Leerink
Thermo Fisher price target raised to $365 from $330 at SVB Leerink
04/23/20 Needham
Thermo Fisher price target raised to $383 from $341 at Needham
04/21/20 Wells Fargo
Danaher price target raised to $170 from $155 at Wells Fargo
03/30/20 Wells Fargo
Thermo Fisher price target lowered to $300 from $345 at Wells Fargo
QGEN Qiagen
$42.08 /

-0.24 (-0.57%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
TMO Thermo Fisher
$343.03 /

+6.54 (+1.94%)

QGEN Qiagen
$42.08 /

-0.24 (-0.57%)

TMO Thermo Fisher
$343.03 /

+6.54 (+1.94%)

QGEN Qiagen
$42.08 /

-0.24 (-0.57%)

TMO Thermo Fisher
$343.03 /

+6.54 (+1.94%)

QGEN Qiagen
$42.08 /

-0.24 (-0.57%)

TMO Thermo Fisher
$343.03 /

+6.54 (+1.94%)

QGEN Qiagen
$42.08 /

-0.24 (-0.57%)

Earnings
Qiagen sees growth trends from first half continuing for the full year » 16:17
05/06/20
05/06
16:17
05/06/20
16:17
QGEN

Qiagen

$41.88 /

+0.11 (+0.26%)

Roland Sackers, CFO of…

Roland Sackers, CFO of QIAGEN, said: "QIAGEN's solid financial position has allowed us to react swiftly and make investments in the expansion of production capacity in Europe and the United States to support COVID-19 testing. Our priorities during this time have balanced the urgent needs of our customers while also ensuring the health and safety of our employees. We currently anticipate the growth trends from the first half of 2020 to continue for the full year, but cannot reliably predict to what extent this will occur due to uncertainties regarding the future trends of the coronavirus pandemic. Consequently, we have decided to suspend the outlook for the full year at this time."

ShowHide Related Items >><<
QGEN Qiagen
$41.88 /

+0.11 (+0.26%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.